Pulse Biosciences Q3 net loss widens 19% year over year to $23.05 million

Bitget2026/11/05 21:25

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold. Trade now!

A welcome pack worth 6200 USDT for new users! Sign up now!

Pulse Biosciences’ third-quarter 2026 GAAP net loss widened 19% year over year to $23.05 million.
Revenue rose year over year to $395,000, while GAAP costs and expenses increased 21% to $24.69 million.
Cash, cash equivalents and marketable securities climbed 86% from June 30 to $189.2 million at September 30, 2026.
NANOPULSE-AF completed enrollment with 169 evaluable patients, three months ahead of plan.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Pulse Biosciences Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 202611051605BIZWIRE_USPR_____20261105_BW622360) on November 05, 2026, and is solely responsible for the information contained therein.

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.

Trade now！

Pulse Biosciences Q3 net loss widens 19% year over year to $23.05 million

You may also like

Crypto prices